KRAS Mutation Test: Colon, Lung, Pancreatic Cancer, and Results

A KRAS mutation test identifies acquired changes in one of the most common cancer-driving genes. Its clinical meaning depends strongly on the tumor type and exact variant. In metastatic colorectal cancer, any activating KRAS or NRAS mutation usually predicts lack of benefit from anti-EGFR antibodies such as cetuximab or panitumumab, while KRAS G12C can open a targeted combination option after prior therapy. In non-small cell lung cancer, KRAS G12C has approved targeted treatments, but other KRAS variants are generally managed through chemotherapy, immunotherapy, or clinical trials. In pancreatic ductal adenocarcinoma, KRAS mutations are present in most tumors, commonly G12D, G12V, or G12R; the result supports tumor biology but only selected variants currently have established targeted options. Testing should report the exact codon, amino acid change, specimen, variant allele fraction, and assay coverage. A negative result can be equally important because it may prompt a search for another actionable driver or raise questions about specimen quality.

• KRAS mutations are found in about 40% of colorectal cancers, 25% to 30% of lung adenocarcinomas, and up to 90% of pancreatic ductal adenocarcinomas.
• In metastatic colorectal cancer, an activating KRAS or NRAS mutation predicts resistance to anti-EGFR antibody treatment.
• KRAS G12C is targetable in defined lung and colorectal cancer settings, but G12D, G12V, G12R, and other variants are not interchangeable.
• A negative KRAS result should be interpreted with tumor content and panel coverage and may lead to testing for BRAF, EGFR, ALK, ROS1, NTRK, HER2, or other drivers.
• Tumor KRAS mutations are usually acquired; inherited KRAS-related syndromes are rare and are evaluated separately.

Table of Contents

• What the KRAS test detects
• KRAS in colorectal cancer
• KRAS in lung cancer
• KRAS in pancreatic cancer
• Specimens, methods, and timing
• Reading positive, negative, and changing results
• Treatment, follow-up, and questions

What the KRAS test detects

KRAS encodes a small GTPase that works like a molecular switch. Growth-factor receptors activate KRAS by loading it with GTP. KRAS then sends signals through RAF-MEK-ERK, PI3K-AKT, and other pathways that promote cell growth and survival. Normal KRAS turns itself off by converting GTP to GDP. Activating mutations interfere with that shutoff step, leaving the signal on.

Most clinically important variants affect codons 12, 13, or 61. Less common changes occur at codons 59, 117, or 146. Reports use protein notation such as p.G12C, p.G12D, or p.Q61H. The letter before the number is the normal amino acid; the final letter is the replacement. G12C therefore means glycine at position 12 has changed to cysteine.

The exact change is crucial. G12C contains a cysteine that can be bound by variant-specific inhibitors. G12D, G12V, and G12R do not have that same drug-binding site. Two tumors can both be “KRAS positive” while having different biology, tissue distribution, and treatment options.

Common patterns include:

Variant	Tumors in which it is often seen	Current practical relevance
G12C	Lung adenocarcinoma, colorectal cancer, smaller fraction of pancreatic cancer	Approved variant-specific inhibitors in defined settings
G12D	Pancreatic, colorectal, lung cancer	Common driver; targeted agents remain mainly investigational
G12V	Pancreatic, colorectal, lung cancer	Common driver; no broadly established direct inhibitor
G12R	Pancreatic cancer	Distinct biology; targeted strategies mostly investigational
G13D	Colorectal cancer	Predicts anti-EGFR resistance under standard practice
Q61 variants	Colorectal, lung, melanoma and others	Activating; treatment meaning depends on tumor type

KRAS, NRAS, and HRAS belong to the RAS family. For colorectal treatment decisions, laboratories usually test both KRAS and NRAS across exons 2, 3, and 4. Testing codon 12 alone is incomplete because less common activating variants also predict resistance to anti-EGFR antibodies.

Most cancer-associated KRAS mutations are somatic. They are found in the tumor and are not passed to children. Rare germline KRAS variants cause developmental conditions in the RASopathy spectrum, but these are not diagnosed from a routine tumor test. If a tumor-only result has an unusual variant, a near-50% allele fraction, and a suggestive lifelong history, genetics review may be appropriate.

KRAS testing is not a stand-alone cancer diagnostic. A mutation can support that a pancreatic cyst or small specimen contains neoplastic cells, but it cannot by itself establish tumor type, stage, or aggressiveness. Pathology and imaging remain essential.

KRAS in colorectal cancer

KRAS testing is standard for metastatic colorectal cancer because it predicts whether anti-EGFR antibodies are likely to work. Cetuximab and panitumumab block EGFR at the cell surface. If KRAS or NRAS is already activated downstream, blocking EGFR usually cannot stop the signal. An activating RAS mutation is therefore a negative predictive biomarker for these drugs.

Testing should use tumor tissue from the primary cancer or a metastasis. RAS status is generally stable enough that either can be used, although rare differences arise through tumor heterogeneity or treatment selection. A broad panel is efficient because it can assess KRAS, NRAS, BRAF, HER2 amplification, mismatch-repair status, and rare fusions.

For metastatic disease, “RAS wild type” means no activating KRAS or NRAS variant was detected in the required regions. It does not automatically mean anti-EGFR treatment is the best choice. Tumor side, BRAF status, HER2 amplification, mismatch-repair status, previous treatments, symptoms, and treatment goals also matter. Anti-EGFR therapy tends to provide the greatest first-line benefit in left-sided, RAS-wild-type tumors.

A KRAS mutation usually excludes cetuximab or panitumumab as standard therapy, with an important exception: KRAS G12C colorectal cancer can be treated with a G12C inhibitor plus EGFR blockade in defined later-line settings. Colorectal tumors activate feedback through EGFR when KRAS G12C is inhibited, so combination therapy works better than a G12C inhibitor alone. Available regimens and treatment-line requirements vary by jurisdiction and change as trial evidence matures.

KRAS status is not a simple prognosis score. Some variants have been associated with different recurrence or survival patterns, but stage, resectability, tumor burden, mismatch-repair status, treatment, and co-mutations have larger practical effects. A KRAS mutation should not be interpreted as proof that a localized cancer will recur.

In early-stage colon cancer, KRAS is not routinely used by itself to decide whether adjuvant chemotherapy is needed. Stage, lymph nodes, high-risk pathology, mismatch repair, patient health, and in some settings circulating tumor DNA provide more useful guidance. KRAS may be part of a broad profile but should not be overextended beyond validated uses.

KRAS can also be measured in plasma. A positive plasma result can establish RAS-mutant disease when tissue is inadequate. A negative plasma result is less definitive because colorectal cancers vary in DNA shedding, especially with low-volume disease, lung-only metastases, or peritoneal disease. Tissue testing should follow when feasible.

Resistance can change the picture. RAS-wild-type colorectal tumors treated with anti-EGFR antibodies may develop KRAS or NRAS mutations in subclones. These resistance clones can be detected in circulating DNA and may decline after treatment stops. Rechallenge strategies based on plasma RAS clearance are being studied and used selectively, but they require a validated assay and oncology expertise.

KRAS in lung cancer

KRAS is one of the most common drivers in lung adenocarcinoma, particularly in people with a smoking history, although it also occurs in never-smokers. G12C accounts for roughly 40% of KRAS-mutant lung cancers and about 12% to 14% of lung adenocarcinomas in many Western populations. G12V and G12D are also frequent.

Current lung-cancer testing should not stop at KRAS. Broad DNA and RNA profiling can assess EGFR mutations, ALK, ROS1, RET, NTRK and NRG1 fusions, BRAF V600E, MET exon 14 skipping, HER2 mutations, KRAS G12C, and other findings. PD-L1 immunohistochemistry is a separate test used to guide immunotherapy.

A KRAS G12C result can support treatment with a covalent inhibitor such as sotorasib or adagrasib in advanced non-small cell lung cancer after required prior therapy, depending on local approvals. Other G12C inhibitors and combinations continue to emerge. These drugs trap KRAS G12C in its inactive GDP-bound state. They do not inhibit G12D or G12V.

Targeted therapy is not automatically first-line for every G12C-positive lung cancer. First-line treatment commonly depends on PD-L1, disease burden, symptoms, co-mutations, and eligibility for immunotherapy and chemotherapy. Current approvals and guideline sequencing should be checked at the time of treatment because the field is changing rapidly.

Co-mutations help explain why patients with the same KRAS variant can respond differently. STK11, KEAP1, TP53, CDKN2A, and other alterations influence tumor biology and immune response. For example, STK11 or KEAP1 co-mutation is associated in groups of patients with less favorable outcomes to several systemic therapies. These findings are prognostic context, not absolute rules for an individual.

A positive KRAS result usually makes another dominant oncogenic driver less likely, but co-occurrence is possible. Rare tumors contain both KRAS and EGFR alterations or a fusion, especially after treatment. The molecular report and clinical history should be reviewed rather than assuming mutual exclusivity.

Resistance to G12C inhibitors can arise through several mechanisms:

• secondary KRAS changes that prevent drug binding;
• amplification of mutant KRAS;
• activation of EGFR, MET, or other receptor pathways;
• downstream BRAF, MEK, or PI3K pathway changes;
• transformation in tumor histology; or
• growth of a pre-existing non-G12C clone.

Repeat tissue biopsy or plasma profiling at progression can identify some mechanisms and clinical-trial options. Plasma is helpful for rapid, broad assessment, while tissue is needed when histologic transformation is suspected. A negative plasma test should not delay tissue evaluation if progression is clear.

KRAS mutation does not by itself determine whether immunotherapy will work. Smoking-associated KRAS tumors may have a higher mutation burden, but PD-L1, co-mutations, autoimmune history, and patient factors still guide treatment. Some KRAS-mutant tumors respond well to immunotherapy, while others do not.

KRAS in pancreatic cancer

KRAS mutations occur in up to 90% of pancreatic ductal adenocarcinomas. G12D is most common, followed by G12V and G12R. G12C is uncommon, generally around 1% to 3%. This distribution explains why approved G12C drugs apply to only a small fraction of pancreatic cancers.

In a typical pancreatic ductal adenocarcinoma, finding KRAS confirms a common driver but does not usually change first-line chemotherapy. Treatment is guided by stage, resectability, performance status, symptoms, germline testing, and a broader tumor profile. All patients should be considered for inherited cancer testing because BRCA1, BRCA2, PALB2, mismatch-repair genes, and other germline findings can affect therapy and family risk.

Tumor profiling is especially important in advanced disease and in KRAS-wild-type pancreatic cancer. The absence of KRAS may indicate a less common but potentially targetable driver, such as an NTRK, NRG1, ALK, ROS1, RET, or FGFR2 fusion; BRAF alteration; HER2 amplification; or mismatch-repair deficiency. Acinar cell carcinoma, neuroendocrine tumors, and other pancreatic neoplasms also have different molecular patterns. Pathology review can prevent a broad label of “pancreatic cancer” from obscuring a distinct disease.

KRAS testing may be performed on endoscopic ultrasound biopsy, surgical tissue, cytology, pancreatic cyst fluid, or plasma. Small needle biopsies can have low tumor content because pancreatic cancers are often surrounded by dense stroma. A negative result from a scant specimen should not be assumed to represent true wild-type disease without reviewing tumor cellularity and assay sensitivity.

In pancreatic cyst fluid, KRAS and GNAS mutations can support a mucinous cyst diagnosis, but they do not by themselves determine whether high-grade dysplasia or cancer is present. Imaging features, cyst size, mural nodules, duct changes, cytology, symptoms, and other molecular findings are needed. Molecular testing is most useful when it resolves a specific uncertainty that affects surgery or surveillance.

KRAS G12C inhibitors have shown activity in previously treated pancreatic cancer, and access may come through tumor-agnostic or disease-specific approvals, guidelines, or trials depending on location. G12D inhibitors, pan-KRAS inhibitors, RAS-on inhibitors, SHP2 inhibitors, vaccines, and cellular therapies are being studied. A report should distinguish established treatment from clinical-trial potential.

KRAS allele fraction in plasma can reflect tumor burden and treatment response, but pancreatic cancer may shed variable amounts of DNA. A rising known mutation can accompany progression; a negative result after treatment may be encouraging but cannot prove eradication. Imaging and CA 19-9, when informative, remain standard components of follow-up.

Specimens, methods, and timing

KRAS can be tested by allele-specific PCR, digital PCR, Sanger sequencing, targeted NGS, or comprehensive genomic profiling. Focused assays are fast but may cover only common codons. NGS provides broader information and is generally preferred when multiple actionable genes matter.

A strong report includes:

• the exact DNA and protein change;
• the exon and codon;
• the specimen and collection date;
• tumor percentage or plasma fraction when available;
• variant allele fraction;
• the genomic regions and variant types covered;
• the assay’s limit of detection; and
• an interpretation specific to the tumor type.

For colorectal cancer, testing must cover extended RAS regions rather than KRAS exon 2 alone. For lung cancer, an RNA component improves detection of fusions and MET exon 14 skipping that DNA-only tests can miss. For pancreatic cancer, broad profiling is especially useful when KRAS is absent.

Tissue selection matters. A recent metastatic biopsy may better represent current disease after several treatments, but an older high-quality block may contain more tumor and still be adequate for a stable driver. Pathologists choose the block and mark the tumor-rich area. Macrodissection can enrich tumor DNA.

Plasma liquid biopsy can provide results quickly and capture DNA from multiple sites. It is particularly useful when tissue is unsafe or inadequate. Its main weakness is false negativity when the tumor sheds little DNA. A positive actionable result is often clinically useful; a negative result should usually be followed by tissue testing when treatment depends on finding a driver.

Variant allele fraction is not the percentage of the body affected by cancer. In tissue, it reflects tumor purity, copy number, and whether the mutation is in all tumor cells. In plasma, it depends on tumor shedding and the amount of normal cell-free DNA. Cross-laboratory comparisons are unreliable unless the methods are similar.

Turnaround can range from a few days for focused PCR to two or more weeks for broad profiling. In rapidly progressive lung cancer, laboratories may combine rapid hotspot testing with comprehensive profiling. Treatment teams should avoid exhausting a small specimen on sequential single-gene tests when a multiplex assay can answer the full question.

Reading positive, negative, and changing results

A positive result should be read in four parts: exact variant, cancer type, treatment setting, and co-alterations. KRAS G12C in metastatic lung cancer is actionable under different rules from G12C in metastatic colorectal cancer. G12D in pancreatic cancer is a common driver but usually not an established routine target. G13D in colorectal cancer is considered RAS-mutant for anti-EGFR selection.

A negative result means no reportable mutation was detected within the assay’s scope and sensitivity. It does not mean the tumor lacks genetic changes. Important questions are whether enough tumor was present, whether all relevant exons were covered, and whether another driver was found.

Possible explanations for a negative result include:

• true KRAS-wild-type disease;
• low tumor fraction;
• a variant outside the tested hotspots;
• degraded DNA;
• a structural alteration not detected by the assay;
• treatment suppressing the clone; or
• a specimen that does not contain the cancer of interest.

A variant of uncertain significance should not be treated as an activating KRAS mutation unless evidence supports that classification. Most recurrent codon 12, 13, and 61 variants are well established, but rare changes can be difficult to interpret. The laboratory may later reclassify a VUS.

Results can change through clonal evolution. The founding KRAS driver often remains present, but resistance mutations or bypass pathways can emerge. In colorectal cancer, acquired RAS mutations can appear during anti-EGFR therapy. In lung cancer, secondary changes can cause G12C inhibitor resistance. A new sample at progression answers a different question from the original diagnostic sample.

An unexpectedly low VAF may reflect low tumor content or a subclone. If the variant is being used to deny a high-value treatment, confirm that it is technically valid and clinically activating. An unexpectedly high VAF can result from loss of the normal chromosome copy, amplification, or high tumor purity; it does not automatically indicate germline origin.

Discordance between tissue and plasma is not rare. A tissue-positive/plasma-negative pattern usually reflects limited shedding. Plasma-positive/tissue-negative results may reflect tumor heterogeneity, an old tissue block, or occasionally clonal hematopoiesis. KRAS is less commonly a clonal hematopoiesis gene than DNMT3A or TET2, but confirmation may still be needed for a very low-level, atypical plasma finding.

Treatment, follow-up, and questions

KRAS testing should lead to a clear action or documented limitation. In colorectal cancer, it establishes whether anti-EGFR therapy is appropriate and identifies G12C-specific options. In lung cancer, it identifies G12C-directed therapy and provides co-mutation context. In pancreatic cancer, it confirms a common driver and makes a negative result a reason to search broadly for alternatives.

Ask the oncology team:

1. What exact KRAS variant and VAF were found?
2. Was extended KRAS and NRAS testing performed for colorectal cancer?
3. Is the variant an established target in this cancer type and treatment line?
4. What other drivers and resistance genes were tested?
5. Was the specimen adequate, and what was the assay’s detection limit?
6. Should tissue testing follow a negative plasma result?
7. Would repeat profiling at progression change treatment or trial eligibility?
8. Does germline testing need to be done separately?

For people receiving a KRAS G12C inhibitor, monitoring commonly includes liver tests, gastrointestinal symptoms, lung symptoms, drug interactions, and imaging. Severe diarrhea, persistent vomiting, jaundice, unusual fatigue, fever, or new shortness of breath should be reported promptly. Interstitial lung disease or pneumonitis is uncommon but potentially serious.

Imaging remains the main way to measure tumor response. Tumor markers such as CEA or CA 19-9 can support follow-up when they were elevated at baseline, but neither replaces scans. Serial ctDNA may add information in selected settings, yet routine use differs by cancer and disease stage.

A KRAS mutation is not a lifestyle diagnosis and is not caused by a single recent behavior. Tobacco exposure is associated with particular lung-cancer mutation patterns, including G12C, but individual causation cannot be assigned from a molecular report. The result should be used to guide care, not blame.

Family members do not need testing for the tumor KRAS variant in ordinary circumstances. They may need genetic counseling when the patient has pancreatic cancer, early-onset colorectal cancer, multiple primary cancers, or a strong family history, but inherited testing looks for predisposition genes rather than the common tumor KRAS driver.

Keep copies of the pathology and molecular reports. Record which specimen was tested and whether it was collected before or after therapy. As KRAS drugs expand beyond G12C, the exact variant documented today may become more actionable later. Reinterpretation should rely on current guidelines and trial evidence, not on a generic “KRAS-positive” label.

References

• Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial 2023 (RCT)
• Targeted Therapies for Previously “Undruggable” KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib 2024 (Review)
• Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancer 2025 (Review)
• Targeting KRAS in pancreatic cancer 2024 (Review)
• Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer 2024 (Review)
• Fusion genes in pancreatic tumors 2024 (Review)

Disclaimer

This article is educational and does not replace pathology review or treatment planning by an oncology team. KRAS results must be interpreted by exact variant, cancer type, disease stage, specimen quality, and current approvals. New breathing difficulty, severe diarrhea, jaundice, uncontrolled vomiting, or other serious symptoms during treatment require prompt medical evaluation.